The cost profile of single maintenance and reliever therapy, also known as SMART or single-inhaler therapy, was “favorable” compared with traditional asthma therapy, according to data published in ...
The likelihood for asthma and IgE sensitization up to age 24 years was lower among individuals exclusively breastfed for at ...
Affecting approximately 262 million people worldwide, asthma is a chronic condition of the lungs that causes airway inflammation. 1. Typical symptoms include: Breathlessness; Whee ...
Life & Style on MSN
How to clean your home if you have allergies or asthma
The creation of this article included the use of AI and was edited by human content creators. Read more on our AI policy here. Spring brings warmer weather, blooming flowers, and longer days—but for ...
Estimated annual cost of asthma management totaled $2,181 per SMART-prescribed patient compared with $2,235 with traditional ...
Often, other factors are also at play. "Please see a doctor," says Green, "if your cough lasts more than seven to 10 days, ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
Allergies and asthma affect an increasing number of children worldwide, but now an international research group led by DTU has identified a previously unknown mechanism that can reduce the risk of ...
A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...
Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...
What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved depemokimab (Exdensur, GSK plc) as add-on therapy for severe asthma and for chronic rhinosinusitis with nasal polyps (CRSwNP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results